Jefferies Financial Group Inc. Argenx Se Call Options Transaction History

Jefferies Financial Group Inc.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$356.01 - $451.55 $6.66 Million - $8.44 Million	18,700 New	18,700 $8.04 Million
Q4 2023 Feb 13, 2024	SELL	$338.91 - $506.01 $915,057 - $1.37 Million	-2,700 Reduced 52.94%	2,400 $913,000
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $443,220 - $658,115	-1,200 Reduced 19.05%	5,100 $2.51 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $2.27 Million - $2.66 Million	6,300 New	6,300 $2.46 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.5B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.